Akums Launches Gastrointestinal Tract Disorders Drug Post DCGI Approval
Akums Drugs & Pharmaceuticals announced the launch of a combination drug for gastrointestinal tract disorders on Monday. The contract development and manufacturing organization unveiled Rabeprazole and Levosulpiride SR capsules following approval from the Drug Controller General of India (DCGI), as per a statement released by the company.
Sanjeev Jain, Joint Managing Director of Akums Drugs & Pharmaceuticals, highlighted that the medication provides an effective remedy by alleviating symptoms, improving gastrointestinal function, and enhancing the overall well-being of patients.
This launch expands Akums’ portfolio in the pharmaceutical market, reinforcing its commitment to providing innovative and high-quality healthcare solutions to consumers. The introduction of Rabeprazole and Levosulpiride SR capsules is expected to address the growing demand for effective treatments for gastrointestinal disorders in India.
Key Highlights:
- New Drug Launch: Akums Drugs & Pharmaceuticals introduces Rabeprazole and Levosulpiride SR capsules for gastrointestinal tract disorders.
- DCGI Approval: The launch follows approval from the Drug Controller General of India.
- Effective Remedy: The medication aims to alleviate symptoms and enhance gastrointestinal function, improving patient well-being.
- Portfolio Expansion: The launch expands Akums’ portfolio in the pharmaceutical market, catering to the growing demand for gastrointestinal disorder treatments.
The introduction of this combination drug marks a significant milestone for Akums Drugs & Pharmaceuticals, demonstrating its commitment to addressing the healthcare needs of patients across the country. The company continues to innovate and deliver value-driven solutions to enhance the quality of life for individuals affected by gastrointestinal disorders.